Notice: Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Provisional Patent Application Concerning Enhanced 
Substrates for the Protease Activity of Serotype a Botulinum Neurotoxin

Federal Register: November 6, 2009 (Volume 74, Number 214)           
                  Page 57460

AGENCY: Department of the Army, DoD.

ACTION: Notice.

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/252,675 entitled ``Enhanced Substrates for the Protease Activity of 
Serotype a Botulinum Neurotoxin,'' filed October 18, 2009. The United 
States Government, as represented by the Secretary of the Army, has 
rights to this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Assessment, (301) 619-6664, 
both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to the use of enhanced 
substrates for the protease activity of serotype A botulinum 
neurotoxin.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-26787 Filed 11-5-09; 8:45 am]

BILLING CODE 3710-08-P